Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 180
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT07070440 - 1. fázisTaking peopleAssessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 300
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT06813365 - Korai 1. fázisTaking peopleYSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07793500 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Hefei, Hongcun, Jinan, Jining, Kunming, Lanzhou, Liaocheng, Nanchang, Nanning, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Wuxi, Xiamen, Xi’an, Xuzhou, Yantai, Yulin, Zhengzhou, Zibo
- Életkor
- 18 év and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - 1. fázisTaking peopleA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Where
- Changsha, Chongqing, Guangzhou, Shanghai, Taiyuan, Wuhan
- Életkor
- 18 év to 75 év
- People
- 570
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05194982 - 2. fázisTaking peopleA Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
- Where
- Changchun
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05924841 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Nanjing, Xian
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - 3. fázisTaking peoplePhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Xuzhou, Yangzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - 1/2. fázisTaking peopleA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Where
- Beijing, Changchun, Changsha, Chengdu, Fujian, Fuzhou, Guandong, Hangzhou, Hefei, Jinan, Jingzhou, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Weihui, Xi'an, Xiangyang, Xuzhou, Yichang, Zhengzhou
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01 - No phaseNot yet taking people in KínaSegmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 1200
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07698990 - 2. fázisTaking peopleTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 420
- Run by
- TYK Medicines, Inc
See details and how to joinNCT05948813 - 2. fázisTaking peopleA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Where
- Guangzhou, Wuhan
- Életkor
- 18 év and over
- People
- 32
- Run by
- Guangdong Association of Clinical Trials
See details and how to joinNCT07412262 - 2. fázisNot yet taking people in KínaThe Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 34
- Run by
- Fudan University
See details and how to joinNCT07780578 - No phaseTaking peopleStudy on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
- Where
- Chongqing
- Életkor
- 30 év to 80 év
- People
- 10
- Run by
- 958th Army Hospital of the Chinese People's Liberation Army
See details and how to joinNCT07783971 - 2. fázisTaking peopleStudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05987826 - 3. fázisTaking peopleA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Where
- Guangzhou, Shenyang
- Életkor
- 18 év and over
- People
- 442
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07739758 - No phaseTaking peopleClinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 126
- Run by
- Energenx Medical LTD.
See details and how to joinNCT06739031 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - 2. fázisNot yet taking people in KínaThiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07778940 - No phaseTaking peopleThe Shengjing Lung Cancer Cohort (SJ-LCC) Study on Risk Factors for Disease Development and Progression
- Where
- Shenyang
- Életkor
- 18 év to 75 év
- People
- 1500
- Run by
- Shengjing Hospital
See details and how to joinNCT07779005 - 2. fázisTaking peoplePhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07329322 - 2. fázisNot yet taking people in KínaSpatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 43
- Run by
- Sichuan Cancer Hospital and Research Institute
See details and how to joinNCT07775040 - No phaseTaking peoplePD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
- Where
- Guangzhou, Nanchang, Shenzhen, Wenzhou
- Életkor
- 18 év and over
- People
- 150
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07775820 - 3. fázisTaking peopleASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 286
- Run by
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
See details and how to joinNCT07109531 - 2. fázisTaking peopleStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- BeBetter Med Inc
See details and how to joinNCT06514027